---
title: "Avalo Therapeutics, Inc. (AVTX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/AVTX.US.md"
symbol: "AVTX.US"
name: "Avalo Therapeutics, Inc."
industry: "Biotechnology"
---

# Avalo Therapeutics, Inc. (AVTX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.avalotx.com](https://www.avalotx.com) |

## Company Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:10.000Z

**Overall: D (0.75)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 249 / 404 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -76.59% |  |
| Net Profit YoY | -1125.58% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.88 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 263.99M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 192000.00 |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -177.05% | E |
| Profit Margin | -52019.79% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -76.59% | E |
| Net Profit YoY | -1125.58% | E |
| Total Assets YoY | 27.06% | A |
| Net Assets YoY | 302.69% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.19% | D |
| OCF YoY | -76.59% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 26.82% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Avalo Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-177.05%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-52019.79%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-76.59%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-1125.58%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "27.06%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "302.69%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.19%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-76.59%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "26.82%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | Abbvie (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.65 | 289/605 | 0.97 | 0.71 | 0.59 |
| PB | 2.88 | 230/605 | 3.37 | 1.45 | 0.42 |
| PS (TTM) | 1374.96 | 311/605 | 1456.92 | 270.20 | 113.19 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-04T05:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 10 | 91% |
| Overweight | 1 | 9% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 14.99 |
| Highest Target | 48.00 |
| Lowest Target | 24.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/AVTX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/AVTX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/AVTX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.